P3 Health (PIII) Q4 2025 Earnings Transcript

P3 Health Partners reported FY2025 adjusted EBITDA loss of $161.3 million, but management guided 2026 adjusted EBITDA to a $20 million loss to $40 million gain, with a $10 million midpoint implying about $170 million of year-over-year improvement. Revenue was $1.46 billion in 2025 versus $1.50 billion in 2024, while normalized EBITDA improved by $44 million to a $149.1 million loss. The company also added a Nebraska partnership with 29,000 members, about $27 million of incremental 2026 revenue, and ended the year with $25 million of cash.

Analysis

PIII is trying to re-rate from a distressed execution story into a contract-reset story, and the market will likely trade the delta in credibility more than the absolute earnings bridge. The key second-order effect is that management has effectively pulled a large portion of 2026 improvement into the “already signed” bucket, which should compress perceived forecast risk if the contracts hold — but it also raises the bar for any miss, because the upside is now mostly about controllable operating leverage rather than member growth.

The Nebraska glidepath is more important strategically than financially in year one. It creates a template for low-capex geography expansion with deferred risk transfer, which can become a repeatable playbook if execution is clean; the flip side is that it subtly increases complexity in a business that still has limited liquidity, so any working-capital slippage or claims variability could quickly consume the cushion. The $25 million cash balance means this is less a growth-at-all-costs story and more a sequence story: one bad quarter in medical cost trends would force either dilutive financing or a slowdown in the expansion cadence.

The stock’s setup is asymmetric over months, not days: near-term upside comes from the market believing the 75% “run-rate” claim, while downside is concentrated in the first signs that medical margin remains volatile despite contract fixes. Competitively, improved Stars and tighter payer alignment could pressure smaller regional value-based care operators that lack P3’s contract momentum, but the larger threat is not competition — it’s dilution of the turnaround narrative if management has to lean on one-time adjustments or reclassifications again.

The contrarian view is that guidance may be mechanically achievable yet still not investable if the cash conversion doesn’t follow. In other words, EBITDA can turn positive before the business becomes self-funding; the market may overreact to the headline inflection and underweight how fragile the liquidity bridge remains until medical cost control proves durable across several reporting periods.

Key Decisions for Investors

• Speculative long PIIIW common or equity only on weakness, sized small, with a 3-6 month hold: thesis is contract-driven EBITDA inflection and first-mover re-rating, but only if the market starts believing the 75% of improvement is truly locked in.
• Buy PIIIW Jan-2027 calls / buy Jan-2027 call spreads if liquid: the catalyst path is 2-3 quarterly prints showing positive EBITDA trajectory and stable medical margin, with convexity to a credibility re-rate before liquidity becomes an issue.
• Pair trade: long PIIIW vs short a basket of more expensive managed-care/value-based care names that lack similar contract-reset catalysts; this isolates turnaround execution alpha rather than broad healthcare beta.
• Do not average down on any post-earnings drawdown until medical margin and cash conversion stabilize for at least one quarter; the balance sheet is too tight for narrative-only support.
• If you want cleaner exposure to the same secular theme, prefer a vendor/enabler beneficiary long over direct PIIIW equity; PIII is the higher-beta expression, but the execution risk is materially higher than the market may price.